<DOC>
	<DOCNO>NCT00297310</DOCNO>
	<brief_summary>The purpose study evaluate two group kidney transplant recipient , determine proportion patient achieve therapeutic blood concentration tacrolimus Day 3 transplantation . Patients one group treat tacrolimus accord current clinical practice . The group pre-transplant assessment tacrolimus blood level concentration use guide post-transplantation tacrolimus dosing . Tacrolimus medicine slow body 's immune system . For reason , work anti-rejection medicine .</brief_summary>
	<brief_title>Pre-transplant Assessment Tacrolimus Blood Level Concentration , Predictor Tacrolimus Dose Requirements After Kidney Transplantation</brief_title>
	<detailed_description>This study multicentre , open-label , prospective , 2-arm , phase IV study tacrolimus renal transplant recipient . Patients randomize receive current clinical practice pre-transplant pharmacokinetic assessment tacrolimus metabolism use guide post-transplantation tacrolimus dosing , aim increase proportion patient achieve tacrolimus whole blood trough level &gt; 10 ng/mL Day 3 post-transplantation . Patients randomize Group 1 take single dose tacrolimus ( 0.1 mg/kg ) prior transplantation blood sample take determine tacrolimus whole blood concentration 2 hour post-dose . The result blood sample use guide tacrolimus dose post-transplantation . Patients return low tacrolimus blood concentration post-transplantation start dose 0.3 mg/kg/day , whereas patient return high tacrolimus blood concentration post-transplantation start dose 0.1 mg/kg/day . Patients randomize Group 2 also receive single pre-operative dose tacrolimus , tacrolimus whole blood concentration measure 2 hour post-dose . These patient manage per standard care . The primary objective trial compare , two group , proportion patient achieve tacrolimus whole blood trough concentration Â³10 ng/mL Day 3 post-transplantation . The hypothesis perform tacrolimus whole blood concentration assessment 2 hour pre-operative dose ( guide tacrolimus dose post-transplantation ) , lead increase number patient achieve therapeutic blood concentration post-transplant . The tacrolimus whole blood concentration Day 3 post-transplantation marker risk rejection toxicity . A substudy conduct seek examine compare clinical variability absorption profile measurement phenotype ( blood level ) kidney transplant recipient determine nature extent relationship MDR-1 genotype , thus allow predictive cost effective method determine tacrolimus dosing . Pre-transplant : One single tacrolimus dose 0.1 mg/kg/day orally . Post-transplant : 0.15 - 0.3 mg/kg/day two divide tacrolimus dos orally , actual dose guide pre-transplant tacrolimus blood concentration .</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Patient endstage kidney disease suitable candidate primary renal transplantation retransplantation Patient receive kidney transplant cadaveric living ( HLA identical ) donor , least 10 year age , compatible ABO blood type Patients receive graft nonheartbeating donor know significant liver disease , receive graft hepatitis C B positive donor previously receive receive organ transplant kidney take diltiazem , disallow medication 7 day prior , 30 day trial period , take investigational drug past 28 day patient donor know HIV positive</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Tacrolimus</keyword>
	<keyword>Kidney transplantation</keyword>
	<keyword>Transplantation</keyword>
	<keyword>Kidney failure</keyword>
	<keyword>chronic</keyword>
	<keyword>P-Glycoprotein</keyword>
</DOC>